American Diabetes Association Scientific Sessions

American Diabetes Association Scientific Sessions

Perspective from Katherine Sherif, MD
July 07, 2016
3 min read

‘Metabolic reproductive syndrome’ proposed as new name for PCOS

Perspective from Katherine Sherif, MD
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact

NEW ORLEANS — Polycystic ovary syndrome will be renamed to “metabolic reproductive syndrome” as a result of debates and surveys of women affected by the condition and the health professionals who support their care, according to a speaker here.

“It is time to assign a new name that actually reflects the complex features of the condition,” Helena J. Teede, MBBS, FRACP, PhD, professor and head of the Women’s Public Health Research Program at Monash University in Victoria, Australia, said during her presentation. “The new name needs to enhance the recognition of this major public health issue ... and can then lead to greater educational outreach and better public relations.”

Early efforts on a name change included an open debate in 2012 at the International Congress of Endocrinology in which 72% of about 3,500 participants thought that the name PCOS should be changed. Despite the majority, efforts failed because the participants could not decide on a name.

A 2012 NIH panel workshop, which convened to present and discuss information on PCOS, was the catalyst for the name change. The panel resulted in the recommendation that the name PCOS be changed with a preference for metabolic reproductive syndrome, but the panel stopped short of recommending a specific name in its report.

“[The name PCOS] is a distraction, an impediment to progress,” the NIH panel reported. “It causes confusion and is a barrier to effective education and communication. It focuses on ... polycystic ovarian morphology, which is neither necessary nor sufficient to diagnose the condition.”

After the NIH panel, Teede and other health professional and consumer advocacy leaders joined to develop and conduct surveys of women with PCOS and physicians, as well as to facilitate consumer studies and international panels, to determine whether the name should be changed and, if so, to what new name.

The name metabolic reproductive syndrome was then confirmed as preferred by the majority of surveyed patients and health care professionals internationally.

The 1,400 women with PCOS who were surveyed varied in ages and were mostly from the United States and Europe. A majority had the syndrome for more than 5 years.

Only 14 of the surveyed women agreed that the name PCOS should be retained. Additionally, there was consensus that the name PCOS was confusing and should be changed, and increased education for patients and health care providers in combination with a name change is needed, according to the survey results.

The 1,655 surveyed health care professionals — surveyed from around the world — agreed with the surveyed women that the name PCOS should be changed because it is confusing and can be misleading.

Both the women and the physicians agreed on the name metabolic reproductive syndrome as being the most strongly supported.

The process of changing the name will first include a publication of the international position statement and of the consultation and survey results. Then, Teede will work with the editors of women’s health journals to promote using the new terminology. They will also be updating the international guideline with the new name and work to incorporate the change in the ICD code. – by Cassie Homer


Teede H. 3-CE-SY17. Presented at: American Diabetes Association’s Scientific Sessions; June 10-14, 2016; New Orleans.

Disclosure: Teede reports no relevant financial disclosures.